Format

Send to

Choose Destination
Exp Neurol. 2004 Apr;186(2):248-51.

Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection.

Author information

1
Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 30912-2450, USA. sfagan@mail.mcg.edu

Abstract

Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.

PMID:
15026261
DOI:
10.1016/j.expneurol.2003.12.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center